JOYN Advisors’s Myriad Genetics MYGN Stock Holding History

JOYN Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-85	Closed	-$2K	–	924
2018 Q4	$2K	Buy	85 +80	+1,600%	+$2.88K	﹤0.01%	1508
2018 Q3	$0	Buy	+5	New	+$222	﹤0.01%	1840

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JOYN Advisors's MYGN Position: Q1 2019 in Review

JOYN Advisors sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 85 shares — an estimated $2K sold.

JOYN Advisors first reported a position in MYGN in Q3 2018 and held it in 2 quarters. The position peaked at $2K in Q4 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

JOYN Advisors reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
JOYN Advisors sold 85 Myriad Genetics shares in Q1 2019, an estimated $2K.
JOYN Advisors first reported a position in Myriad Genetics in Q3 2018 and held it in 2 quarters.
JOYN Advisors's Myriad Genetics position peaked at $2K in Q4 2018.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.